Miyazaki Toru

Affiliation and department：
Job title： President, Director
Homepage URL (1)： https://iamaim.jp/

Research field (1)： Molecular biology

Research theme for competitive and other funds (7)：

2018 - 2021 脂肪肝肝癌の発症機序におけるAIMの関連に関する研究
2016 - 2021 Elucidation of the mechanism required for AIM activation, and its therapeutic application to NASH-induced hepatocellular carcinoma
2013 - 2016 Obesity and liver diseases: towards clarification of mechanisms for NASH
2012 - 2015 Development of prophylaxis and therapy system for metabolic stmdorome by regulation of AIM function
2009 - 2009 ナノ・バイオロジーを用いたプロピオン酸血症治療への挑戦

Show all

Papers (105)：

Keisuke Yasuda, Shieri Shimodan, Natsumi Maehara, Aika Hirota, Ruka Iijima, Akemi Nishijima, Haruka Mori, Ran Toyama, Atsumi Ito, Yuri Yoshikawa, et al. AIM/CD5L ameliorates autoimmune arthritis by promoting removal of inflammatory DAMPs at the lesions. Journal of autoimmunity. 2023. 142. 103149-103149
Hotaka Nemoto, Megumi Honjo, Satoko Arai, Toru Miyazaki, Makoto Aihara. Apoptosis inhibitor of macrophages/CD5L enhances phagocytosis in the trabecular meshwork cells and regulates ocular hypertension. Journal of cellular physiology. 2023. 238. 10. 2451-2467
Michiko Takimoto-Sato, Masaru Suzuki, Hiroki Kimura, Haiyan Ge, Munehiro Matsumoto, Hironi Makita, Satoko Arai, Toru Miyazaki, Masaharu Nishimura, Satoshi Konno. Apoptosis inhibitor of macrophage (AIM)/CD5L is involved in the pathogenesis of COPD. Respiratory research. 2023. 24. 1. 201-201
新井郷子, 宮崎徹. 【心血管病の臓器連関】心血管病におけるマクロファージ由来血中タンパク質AIMのかかわり. 循環器内科. 2022. 92. 6. 642-648
新井郷子, 宮崎徹. 【尿細管と腎線維化】急性腎障害治療薬としてのAIMの展望. 腎と透析. 2022. 93. 6. 912-916

ｍore...

MISC (21)：

Tomoko Yamazaki, Takeshi Okanoue, Toru Miyazaki. Specific activation of apoptosis inhibitor of macrophage (AIM) in patients with NASH-associated hepatocellular carcinoma. HEPATOLOGY. 2017. 66. 1126A-1127A
高畑暁子, 新井郷子, 北田研人, 荒木喜美, 禾千絵子, 牧田侑子, 鈴木仁, 中田純一郎, 宮崎徹, 鈴木祐介. IgA腎症の起炎性免疫複合体形成はAIMに依存する. 日本腎臓学会誌. 2017. 59. 3. 245-245
A. Matsumoto, S. Arai, T. Miyazaki. A role for circulating AIM protein in the pathogenesis of autoimmune type 1 diabetes. EUROPEAN JOURNAL OF IMMUNOLOGY. 2016. 46. 316-316
高畑暁子, 北田研人, 禾千絵子, 新井郷子, 牧田侑子, 鈴木仁, 中田純一郎, 堀越哲, 宮崎徹, 鈴木祐介. AIM/CD5LはIgA腎症におけるIgAの沈着と起炎性を制御する. 日本腎臓学会誌. 2016. 58. 3. 298-298
Akiko Takahata, Kento Kitada, Chieko Nogi, Satoko Arai, Yuko Makita, Hitoshi Suzuki, Junichiro Nakata, Satoshi Horikoshi, Toru Miyazaki, Yusuke Suzuki. AIM(CD5L) REGULATES GLOMERULAR IGA DEPOSITION AND ITS PHLOGOGENISITY IN IGA NEPHROPATHYREGULATES THE GLOMERULAR IGA DEPOSITION AND ITS PHLOGOGENISITY IN IGA NEPHROPATHY. NEPHROLOGY DIALYSIS TRANSPLANTATION. 2016. 31. 101-102

ｍore...

Education (2)：

Work history (4)：

2022/04 - 現在 The Institute for AIM Medicine President, Director
2006/04 - 2022/03 The University of Tokyo Graduate School of Medicine Center for Disease Biology and Integrative Medicine Professor
2000/09 - 2006/04 University of Texas Southwestern Medical Center at Dallas Center for Immunology Associate Professor
1995/09 - 2000/09 Basel Institute for Immunology Principal Investigator

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page